KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
NCT ID: NCT05421429
Last Updated: 2024-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2022-07-07
2024-01-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
KN057 (Cohort 1：HA/HB)
Injection, once a week
KN057 doseⅠ
KN057 subcutaneous (SC) injection
KN057 (Cohort 2：HA/HB)
Injection, once a week
KN057 dose Ⅱ
KN057 SC injection
KN057 (Cohort 3：HA/HB)
Injection, once a week
KN057 dose Ⅱ
KN057 SC injection
KN057 (Cohort 4：HAW/HBW)
Injection, once a week
KN057 dose Ⅲ
KN057 SC injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
KN057 doseⅠ
KN057 subcutaneous (SC) injection
KN057 dose Ⅱ
KN057 SC injection
KN057 dose Ⅲ
KN057 SC injection
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Moderately severe to severe hemophilia A or B (Factor VIII or Factor IX activity ≤2%)
3. Participants who are enrolled into the Non-Inhibitor Cohort must meet the following criteria:
①negtive results of of inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in screening period.
②with ≥6 acute bleeding episodes (spontaneous or traumatic, not including episodes of bleeding during surgery) that required treatment within 6 months before screening and willing to continue to receive on-demand treatment during the study.
③using coagulation factor replacement therapy for more than 50 exposure days before screening.
4. Participants who are enrolled into the Inhibitor Cohort must meet the following criteria:
①positive results of inhibitors to Factor VIII (FVIII) or Factor IX (FIX) in screening period.
②with ≥6 acute bleeding episodes (spontaneous or traumatic, not including episodes of bleeding during surgery) that required treatment within 6 months before screening and willing to continue to receive on-demand treatment during the study.
5. Be willing to undergo a washout period of the original treatment regimen before the administration of KN057: at least 48 hours for recombinant activated coagulation factor Ⅶ (rFⅦa); at least 72 hours for FⅧ and prothrombin complex (PCC); at least 96 hours for FⅨ; For other drugs or investigational products with a long half-life, such as Emicizumab, at least five half-lives should have passed prior to dosing.
6. Be willing to comply with the relevant management regulations of the clinical trial unit, and follow study procedures.
Exclusion Criteria
2. Inherited or acquired bleeding disorder other than hemophilia A or B.
3. Have symptoms or signs related to thromboembolic disease or are receiving thrombolytic/anti-thrombolytic therapy; A history of coronary atherosclerotic diseases, arterial or venous thrombosis, and ischemic diseases of important organs.
4. Conditions that may increase risk of thrombosis: including reduced activity of antithrombin III, protein S or protein C;
5. Must use PCC to treat acute bleeding episodes, and can't be treated with rFVIIa.
6. Ongoing or planned use of immune tolerance induction.
7. Regular use of immunomodulatory therapy, such as regular infusion of immunoglobulin or regular use of hormones.
8. Allergy situation: Allergic to test drugs/similar drugs or excipients; With a history of multiple allergies (two or more); A history of specific reactions, such as sensitivity to heparin or heparin induced thrombocytopenia.
9. Abnormal hematologic parameters: Platelet count≤100×10\^9/L; Hemoglobin \< 100g/L; Fibrinogen level \< LLN; Prothrombin time \> 1.5 times ULN;
10. Abnormal renal or hepatic function: Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \> 3 times ULN; Lactate dehydrogenase (LDH) \> 1.5 times ULN; Total bilirubin (TB) \> 1.5 times ULN; Serum creatinine (Cr) and triglyceride \> ULN; Albumin \< 0.8 times LLN;
11. Chronic active hepatitis B/C (HBV-DNA or HCV-RNA quantitative test indicates viral activity); Human immunodeficiency virus (HIV) antibody positive; Syphilis antibody positive; Previous antiviral treatment within 1 month, or a plan for antiviral treatment within 28 weeks of initial administration.
12. Had major surgery, as judged by the investigator, within 3 months prior to the study or have elective surgery planned within 28 weeks of initial administration.
13. Need to use anti-fibrinolytic drugs or drugs affecting platelet function 5 days before administration or 28 weeks after initial administration, including Traditional Chinese medicine/proprietary Chinese medicine, such as aspirin and other non-steroidal anti-inflammatory drugs, Angelica, astragalus, etc., or proprietary Chinese medicine containing the above ingredients.
14. Participated in clinical trials related to coagulation factors within 1 month; Participated in any other drug clinical trials within 3 months.
15. Vaccination within 1 month, or within 28 weeks after initial administration, including inactivated vaccines, live attenuated vaccines, recombinant protein vaccines, recombinant adenovirus vaccines, RNA vaccines, DNA vaccines, etc.;
16. Subjects with fertile partners are not willing to use effective contraception during the study period and for 3 months after the last dosing; Effective contraceptive methods include: vasectomy, adhere to the scientific use of male condoms, etc.
17. Other factors that the investigator considers unacceptable for participation in the study.
18 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Suzhou Alphamab Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Renchi Yang, Doctor
Role: PRINCIPAL_INVESTIGATOR
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Shujie Wang, Doctor
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College Hospital
Hu Zhou, Doctor
Role: PRINCIPAL_INVESTIGATOR
Henan Cancer Hospital（The Affiliated Cancer Hospital Of ZhengZhou University)
Ziqiang Yu, Doctor
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of Soochow University
Changcheng Zheng, Doctor
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of USTC (Anhui Provincial Hospital)
Jing Sun, Doctor
Role: PRINCIPAL_INVESTIGATOR
Nanfang Hospital, Southern Medical University
Xielan Zhao, Doctor
Role: PRINCIPAL_INVESTIGATOR
Xiangya Hospital of Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
stitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KN057-A-201
Identifier Type: -
Identifier Source: org_study_id